- Home
- RPTX vs PASG Comparison
RPTX vs PASG Comparison
Compare RPTX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- PASG
- Stock Information
- Founded
- RPTX 2016
- PASG 2017
- Country
- RPTX Canada
- PASG United States
- Employees
- RPTX N/A
- PASG N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- PASG Health Care
- Exchange
- RPTX Nasdaq
- PASG Nasdaq
- Market Cap
- RPTX 38.3M
- PASG 31.1M
- IPO Year
- RPTX 2020
- PASG 2020
- Fundamental
- Price
- RPTX $1.36
- PASG $0.35
- Analyst Decision
- RPTX Strong Buy
- PASG Strong Buy
- Analyst Count
- RPTX 3
- PASG 3
- Target Price
- RPTX $4.50
- PASG $7.67
- AVG Volume (30 Days)
- RPTX 508.5K
- PASG 193.4K
- Earning Date
- RPTX 05-20-2025
- PASG 05-20-2025
- Dividend Yield
- RPTX N/A
- PASG N/A
- EPS Growth
- RPTX N/A
- PASG N/A
- EPS
- RPTX N/A
- PASG N/A
- Revenue
- RPTX $53,477,000.00
- PASG N/A
- Revenue This Year
- RPTX N/A
- PASG N/A
- Revenue Next Year
- RPTX $7.14
- PASG N/A
- P/E Ratio
- RPTX N/A
- PASG N/A
- Revenue Growth
- RPTX 4.58
- PASG N/A
- 52 Week Low
- RPTX $0.89
- PASG $0.30
- 52 Week High
- RPTX $4.29
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- RPTX 59.23
- PASG 46.97
- Support Level
- RPTX $1.25
- PASG $0.33
- Resistance Level
- RPTX $1.48
- PASG $0.42
- Average True Range (ATR)
- RPTX 0.11
- PASG 0.04
- MACD
- RPTX 0.01
- PASG 0.01
- Stochastic Oscillator
- RPTX 57.14
- PASG 33.27
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.